Multiple myeloma (MM) is a malignant B-cell neoplasm that accounts for 15-20% of all hematologic malignancies and is the second most common blood cancer affecting adults. The disease is characterized by clonal proliferation of malignant plasma cells producing monoclonal proteins with subsequent organ damage leading to development of anemia, renal dysfunction, hypercalcemia, and bone lesions. Diagnosis of MM includes integration of laboratory testing, bone marrow evaluation and imaging including positron emission tomography computed tomography (PET-CT) and whole-body magnetic resonance imaging (MRI).
Introduction and Overview
Treatment paradigms for newly diagnosed patients with MM have evolved significantly in recent years, incorporating novel therapeutic agents, improved supportive care strategies, and personalized medicine approaches (1). These advances in treatment have substantially improved patient outcomes. In randomized clinical trials, patients eligible for high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) (approximately 60% of cases) achieve survival of 10 years or longer (2). However, nearly all patients relapse after initial remission and the disease eventually becomes refractory to therapy, underscoring the need for long-term outcome optimization. This article reviews the contemporary management strategies for patients with newly diagnosed disease.
Contemporary induction therapy for newly diagnosed MM typically consists of triplet/quadruplet regimens combining immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies and corticosteroids. The most commonly utilized regimens in 2026 include:
Daratumumab, a CD38-directed monoclonal antibody, has become a cornerstone agent in induction therapy. Studies have demonstrated that daratumumab-based induction regimens improve depth of response compared to triplet therapies alone, resulting in higher rates of complete response and measurable residual disease (MRD) negativity (2,3).
Proteasome inhibitors remain fundamental components of induction therapy. Bortezomib, the first-generation agent, continues to be widely used, while second-generation proteasome inhibitors such as carfilzomib offer improved tolerability profiles. Lenalidomide and pomalidomide serve as immunomodulatory agents that enhance natural killer cell function and possess direct anti-myeloma activity.
The choice between different proteasome inhibitors often depends on patient-specific factors, including renal function, peripheral neuropathy risk, and cardiovascular comorbidities. Carfilzomib may be preferred in patients with significant baseline neuropathy, while bortezomib remains appropriate for many patients given its extensive clinical validation.
Daratumumab and isatuximab represent second-generation monoclonal antibodies that have transformed myeloma treatment. Daratumumab targets CD38, a highly expressed antigen on myeloma cells, while isatuximab targets CD54. The integration of these agents into induction regimens has become standard practice, with most newly diagnosed patients now receiving daratumumab as part of their initial therapy.
The addition of monoclonal antibodies to traditional triplet therapy has demonstrated superior progression-free survival (PFS) and overall survival (OS) benefits, particularly in high-risk disease stratified by cytogenetic abnormalities such as del(17p), t(4;14), and t(14;16).
Autologous stem cell transplantation remains a cornerstone procedure for eligible newly diagnosed patients and has been shown to improve PFS but not OS. (4) Patient eligibility is determined by age, comorbidity status, and organ function rather than chronologic age alone. Following induction therapy, eligible patients proceed to stem cell mobilization, collection, and high-dose chemotherapy with melphalan conditioning followed by autologous stem cell reinfusion. Tandem autologous transplantation, involving two sequential transplant procedures, continues to benefit selected patients with high-risk disease.
Post-transplant consolidation therapy has become increasingly important in deepening responses achieved during induction and transplantation. Consolidation typically involves additional cycles of chemotherapy designed to eliminate residual disease and improve long-term outcomes.
Maintenance therapy following transplantation or induction therapy (for transplant-ineligible patients) has demonstrated significant benefits in prolonging PFS. Standard maintenance approaches include lenalidomide monotherapy or bortezomib-based combinations, continued until disease progression.
Patients with high-risk cytogenetics receive intensified treatment approaches. Triple and quadruple induction therapy combinations, early transplantation, and extended maintenance strategies are employed for these patients.
The International Myeloma Working Group response criteria define benchmarks for disease control (5). Monthly monitoring of measurable M protein levels in serum and urine is standard during treatment. Evaluation of MRD using next generation flow cytometry (NGF) or next‐generation sequencing (NGS) with high sensitivity (at least one in 105 cells) provides detection of residual bone marrow plasma cells. Sustained MRD‐negativity requires confirmed MRD‐negativity in bone marrow in two samples at least one year apart. Imaging‐positive MRD‐negativity combines NGF/NGS with PET/CT clearance of all tracer uptake found at baseline.
While MRD‐negativity does not entirely prevent relapses, it serves as a critical prognostic marker and may help to guide treatment strategies, as it is associated with improved PFS and OS.
Comprehensive supportive care remains essential throughout treatment. Bone protective agents such as bisphosphonates or denosumab prevent skeletal complications, antimicrobial prophylaxis reduces infection risk, and management of cytopenias ensures treatment tolerance. Monitoring for treatment-related toxicities, including peripheral neuropathy, cardiomyopathy, and secondary malignancies, guides therapy modifications.
Treatment of newly diagnosed multiple myeloma in 2026 represents a sophisticated, multidrug approach emphasizing both disease control and quality-of-life. Integration of novel therapeutic agents, refined risk stratification, and personalized medicine approaches promise to support improvements in patient outcomes. Future directions include deeper investigation of MRD-driven treatment modifications and exploration of novel therapeutic targets.
Author:
Julie Rosenberg, MD
Linical